Impact of Respiratory Syncytial Virus (RSV) in Adults 60 Years and Older in Spain

<b>Background/Objectives</b>: Respiratory illnesses frequently lead to hospitalization in adults aged 60 and older, especially due to respiratory viral infectious (RVI). This study investigates hospitalization patterns and characteristics of RVI at HM Hospitals from October 2023 to March 2024; <b>Methods</b>: We retrospectively explored hospitalizations of patients aged 60 years and older with RVIs, gathering data on demographics, clinical profiles, comorbidities, and treatments. Outcomes included hospitalization, ICU admissions, and mortality, and independent factors associated with outcomes were identified using a multi-state model; <b>Results</b>: From October 2023 to March 2024, from a total of 3258 hospitalizations, 1933 (59.3%) were identified as positive for RVIs. Overall, SARS-CoV-2 was the most prevalent (52.6%), followed by influenza (32.7%), and RSV (11.8%). Most RVI involved single infections (88.2%). Hospitalization rates increased with age for SARS-CoV-2 (333.4 [95% CI: 295.0-375.2] to 651.6 [95% CI: 532.1-788.4]), influenza (169.8 [95% CI: 142.6-200.7] to 518.6 [95% CI: 412.1-643.1]), and RSV (69.2 [95% CI: 52.2-90.0] to 246.0 [95% CI: 173.8-337.5]), with SARS-CoV-2 showing the highest rate, followed by influenza and RSV. In the multi-state model, RSV infection significantly increased ICU admission risk (HR: 2.1, 95%, <i>p</i> = 0.037). Age on admission (HR: 1.1, 95%, <i>p</i> < 0.001) and Charlson score (HR: 1.4, 95%, <i>p</i> = 0.001) were associated with transitioning from admission to death. ICU to death risks included age at admission (HR: 1.7, 95%, <i>p</i> < 0.001); <b>Conclusions</b>: RVI in adults 60 years and older are associated with high hospitalization and mortality rates, primarily driven by influenza and SARS-CoV-2, followed by RSV. Age and comorbidities significantly impact disease severity, emphasizing the need for targeted prevention and management strategies for RSV in this vulnerable population.